Women’s Health Bulletin

Published by: Kowsar
Crossmark

The Effect of Magnesium Oxide on Hyperphosphatemia in Female Hemodialysis Patients

Maryam Pakfetrat 1 , Shokouh Sharifpour 2 , Leila Malekmakan 3 , * , Shahrokh Ezzatzadegan Jahromi 1 , Jamshid Roozbeh 1 and Amir Aslani 4
Authors Information
1 Department of Internal Medicine, Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Community Medicine, Shiraz Nephro Urology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Women's Health Bulletin: June 16, 2014, 1 (2); e20048
  • Published Online: June 11, 2014
  • Article Type: Research Article
  • Received: March 17, 2014
  • Revised: April 2, 2014
  • Accepted: May 10, 2014
  • DOI: 10.17795/whb-20048

How to Cite: Pakfetrat M, Sharifpour S, Malekmakan L, Ezzatzadegan Jahromi S, Roozbeh J, et al. The Effect of Magnesium Oxide on Hyperphosphatemia in Female Hemodialysis Patients, Women Health Bull. 2014 ; 1(2):e20048. doi: 10.17795/whb-20048.

Abstract
Copyright © 2014, Health Policy Research Center, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Pendse S, Singh A. Handbook of dialysis. 2007; : 8
  • 2. Daugirdas J. Handbook of dialysis. 2007; : 168
  • 3. Coyne D, Cheng S, Delmez JA. Handbook of dialysis. 2007; : 589 -91
  • 4. Kanbay M, Goldsmith D, Uyar ME, Turgut F, Covic A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010; 29(3) : 280 -92 [DOI][PubMed]
  • 5. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996; 49(1) : 163 -7 [PubMed]
  • 6. Fournier A, Moriniere P. Magnesium hydroxide is a useful complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis. Clin Nephrol. 1988; 29(6) : 319 [PubMed]
  • 7. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res. 2001; 14(4) : 257 -62 [PubMed]
  • 8. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int. 2006; 10(4) : 338 -45 [DOI][PubMed]
  • 9. Ketteler M. Phosphorus Control in Chronic Kidney Disease. Eur Ren Genitourin Dis. 2007; 1(24) : 18 -21
  • 10. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20(2) : 388 -96 [DOI][PubMed]
  • 11. Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol. 2008; 40(1) : 193 -201 [DOI][PubMed]
  • 12. Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens. 2002; 11(4) : 403 -10 [PubMed]
  • 13. Spiegel DM, Farmer B, Smits G, Chonchol M. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study. J Ren Nutr. 2007; 17(6) : 416 -22 [DOI][PubMed]
  • 14. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010; 25(11) : 3707 -17 [DOI][PubMed]
  • 15. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet. 1986; 1(8486) : 880 -2 [PubMed]
  • 16. Deuber HJ. Long-term efficacy and safety of an oral phosphate binder containing both calcium acetate and magnesium carbonate in hemodialysis patients. Nieren-und Hochdruckkrankheiten. 2004; 33(8) : 403–8 [DOI]
  • 17. Parsons V, Papapoulos SE, Weston MJ, Tomlinson S, O'Riordan JL. The long-term effect of lowering dialysate magnesium on circulating parathyroid hormone in patients on regular haemodialysis therapy. Acta Endocrinol (Copenh). 1980; 93(4) : 455 -60 [PubMed]
  • 18. Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol. 1991; 53 : 299 -307 [DOI][PubMed]
  • 19. Moriniere P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant. 1988; 3(5) : 651 -6 [PubMed]
  • 20. Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982; 30(2) : 114 -7 [PubMed]
  • 21. Coladonato JA. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol. 2005; 16 Suppl 2 -14 [DOI][PubMed]
  • 22. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, Donker AJ. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol. 1987; 28(4) : 180 -5 [PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments